Breaking News Instant updates and real-time market news.

TXN

Texas Instruments

$88.71 /

-5.75 (-6.09%)

, ADI

Analog Devices

$80.59 /

-5.31 (-6.18%)

06:58
01/04/19
01/04
06:58
01/04/19
06:58

BofA downgrades TI, Analog Devices, Maxim Integrated in semi ratings shake-up

As previously reported, BofA Merrill Lynch analyst Vivek Arya downgraded Texas Instruments (TXN), Analog Devices (ADI) and Maxim Integrated (MXIM), all to Neutral from Buy, stating that despite their solid execution and attractive free cash flow yields he sees limited multiple expansion until global growth starts to recover. Arya, who also upgraded Intel (INTC) to Buy this morning, forecasts total semiconductor industry sales to decelerate in 2019 and still expects enterprise, data center and parts of networking infrastructure to perform better than cyclical sectors such as industrial, automotive and smartphones. In addition to cutting his estimates for all three downgraded stocks, he lowered his price target on TI shares to $105 from $117, cut his target on Analog Devices to $96 from $112 and trimmed his target on Maxim to $57 from $58.

TXN

Texas Instruments

$88.71 /

-5.75 (-6.09%)

ADI

Analog Devices

$80.59 /

-5.31 (-6.18%)

MXIM

Maxim Integrated

$47.86 /

-3.02 (-5.94%)

INTC

Intel

$44.49 /

-2.6 (-5.52%)

  • 04

    Jan

  • 06

    Jan

  • 07

    Jan

  • 07

    Jan

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

  • 15

    Jan

  • 29

    Jan

  • 25

    Feb

TXN Texas Instruments
$88.71 /

-5.75 (-6.09%)

01/04/19 BofA
Texas Instruments downgraded to Neutral from Buy at BofA/Merrill
01/03/19 Morgan Stanley
Skyworks, Qorvo among semi names with most Apple exposure, says Morgan Stanley
12/03/18 UBS
Meaningful reset in Street semiconductor growth expectations coming, says UBS
11/07/18 Benchmark
Diodes results, guidance 'much better' than feared, says Benchmark
ADI Analog Devices
$80.59 /

-5.31 (-6.18%)

01/04/19 BofA
Analog Devices downgraded to Neutral from Buy at BofA/Merrill
01/04/19 RBC Capital
Analog Devices downgraded to Sector Perform from Outperform at RBC Capital
12/19/18
Fly Intel: Top five analyst downgrades
MXIM Maxim Integrated
$47.86 /

-3.02 (-5.94%)

01/04/19 BofA
Maxim Integrated downgraded to Neutral from Buy at BofA/Merrill
12/18/18 Barclays
Cisco acquisition of Luxtera a negative for Macom, says Barclays
10/31/18 Truist
Maxim Integrated price target lowered to $51 from $60 at SunTrust
10/31/18 Jefferies
Maxim Integrated should be bought on guidance selloff, says Jefferies
INTC Intel
$44.49 /

-2.6 (-5.52%)

01/04/19
BofA/Merrill prefers cloud and 5G exposure in semis, upgrades Intel to Buy
01/04/19 BofA
Intel upgraded to Buy from Neutral at BofA/Merrill
12/27/18 RBC Capital
Nvidia, AMD estimates lowered at RBC Capital on more cautious gaming view

TODAY'S FREE FLY STORIES

General news
FX Action: USD-JPY is higher » 04:25
09/21/21
09/21
04:25
09/21/21
04:25
$ECON

Economic Data

/

+

FX Action: USD-JPY is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
European stock markets are broadly higher » 03:35
09/21/21
09/21
03:35
09/21/21
03:35
$ECON

Economic Data

/

+

European stock markets…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
The FOMC is front and center this week » 02:10
09/21/21
09/21
02:10
09/21/21
02:10
$ECON

Economic Data

/

+

The FOMC is front and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
U.S. current account preview » 02:00
09/21/21
09/21
02:00
09/21/21
02:00
$ECON

Economic Data

/

+

U.S. current account…

U.S. current account preview: the deficit is expected to narrow to -$189.9 B in Q2 after widening to a 15-year high of -$195.7 B in Q1. Analysts saw a -$208.4 B goods and services trade deficit in Q2. As a percentage of nominal GDP, the gap is expected to sit at -3.3% in Q2, down from -3.6%. Analysts saw Q2 growth for goods, services, and income of 26.6% for exports and 20.6% for imports, as global trade in goods and services continues to rebound from the COVID-19 hit. Analysts expect an annual current account deficit of -$740 B in 2021, versus a high from the last expansion of -$480 B in 2019. The deficit is sitting near to the -$806 B record gap back in 2006.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
U.S. housing starts preview » 02:00
09/21/21
09/21
02:00
09/21/21
02:00
$ECON

Economic Data

/

+

U.S. housing starts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

Initiation
Gossamer Bio assumed with an Overweight at Piper Sandler » 21:25
09/20/21
09/20
21:25
09/20/21
21:25
GOSS

Gossamer Bio

$10.26 /

-0.29 (-2.75%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi assumed coverage of Gossamer Bio with an Overweight rating and $26 price target. The analyst has "strong conviction" on both the company's clinical stage assets: Seralutinib for pulmonary arterial hypertension and GB004 for ulcerative colitis. The analyst is positive on the shares into the two second half of 2021 data readouts.

ShowHide Related Items >><<
GOSS Gossamer Bio
$10.26 /

-0.29 (-2.75%)

GOSS Gossamer Bio
$10.26 /

-0.29 (-2.75%)

03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
10/16/20 Barclays
Gossamer Bio price target lowered to $18 from $22 at Barclays
GOSS Gossamer Bio
$10.26 /

-0.29 (-2.75%)

  • 30
    Oct
Hot Stocks
Designer Brands executive chairman buys 1.49M share of common stock » 21:05
09/20/21
09/20
21:05
09/20/21
21:05
DBI

Designer Brands

$13.26 /

+0.405 (+3.15%)

In a regulatory filing,…

In a regulatory filing, Designer Brands disclosed that its executive chairman Jay Schottenstein bought 1.496M shares of common stock on September 16th in a total transaction size of $19.1M, boosting his stake by about 47%.

ShowHide Related Items >><<
DBI Designer Brands
$13.26 /

+0.405 (+3.15%)

DBI Designer Brands
$13.26 /

+0.405 (+3.15%)

09/01/21 Deutsche Bank
Designer Brands price target raised to $19 from $18 at Deutsche Bank
03/17/21 Deutsche Bank
Designer Brands price target raised to $14 from $12 at Deutsche Bank
01/21/21 Deutsche Bank
Designer Brands price target raised to $12 from $7 at Deutsche Bank
01/08/21 CL King
Designer Brands named a top pick for 2021 at CL King
DBI Designer Brands
$13.26 /

+0.405 (+3.15%)

DBI Designer Brands
$13.26 /

+0.405 (+3.15%)

Hot Stocks
Medical Properties Trust enters into 15-year master lease with HCA Healthcare » 20:58
09/20/21
09/20
20:58
09/20/21
20:58
MPW

Medical Properties Trust

$20.19 /

+0.14 (+0.70%)

, HCA

HCA Healthcare

$254.98 /

-3.78 (-1.46%)

Medical Properties Trust…

Medical Properties Trust (MPW) "announced that it has entered into an agreement to lease substantially all of its Utah hospitals to HCA Healthcare (HCA), following an agreement by HCA Healthcare to purchase the operations of five Utah facilities from Steward Health Care System, for which the financial terms of the sale will remain confidential. MPT's purchase price of $1.2B for the Utah hospitals represents approximately 5.0% of the company's total pro forma gross assets, which will place HCA Healthcare among the five largest tenants in the MPT portfolio. Following completion of this agreement with HCA Healthcare and closing of other recently announced transactions, the percentage of MPT's portfolio represented by Steward assets is expected to decrease to approximately 17%."

ShowHide Related Items >><<
MPW Medical Properties Trust
$20.19 /

+0.14 (+0.70%)

HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

MPW Medical Properties Trust
$20.19 /

+0.14 (+0.70%)

08/11/21 RBC Capital
Medical Properties Trust upgraded to Outperform at RBC Capital on valuation
08/11/21 RBC Capital
Medical Properties Trust upgraded to Outperform from Sector Perform at RBC Capital
07/14/21 Mizuho
Medical Properties Trust assumed with a Buy at Mizuho
07/06/21 BofA
Medical Properties downgraded to Neutral on funding needs at BofA
HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

09/09/21 Cowen
HCA's EBITDA outperformance remains underestimated, says Cowen
09/09/21 Cowen
HCA Healthcare initiated with an Outperform at Cowen
08/12/21 Barclays
HCA Healthcare assumed at Equal Weight from Overweight at Barclays
07/22/21 Barclays
HCA Healthcare price target raised to $275 from $225 at Barclays
MPW Medical Properties Trust
$20.19 /

+0.14 (+0.70%)

HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

  • 07
    Jan
MPW Medical Properties Trust
$20.19 /

+0.14 (+0.70%)

HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

MPW Medical Properties Trust
$20.19 /

+0.14 (+0.70%)

HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

Recommendations
Herc Holdings price target raised to $158 from $145 at Baird » 20:41
09/20/21
09/20
20:41
09/20/21
20:41
HRI

Herc Holdings

$125.41 /

-4.1 (-3.17%)

Baird analyst Mircea…

Baird analyst Mircea Dobre raised the firm's price target on Herc Holdings to $158 from $145 and keeps an Outperform rating on the shares. The analyst cites the company's guidance raise and the management's "robust" three-year growth plan.

ShowHide Related Items >><<
HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

09/16/21 Baird
Ashtead results positive for United Rentals and Herc, says Baird
07/23/21 Barclays
Herc Holdings price target raised to $135 from $128 at Barclays
07/22/21 Baird
Herc Holdings price target raised to $145 from $135 at Baird
07/14/21 Barclays
Herc Holdings price target raised to $128 from $115 at Barclays
HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
09/20/21
09/20
20:25
09/20/21
20:25
AZO

AutoZone

$1,588.97 /

-6.68 (-0.42%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include AutoZone (AZO), consensus $29.87.

ShowHide Related Items >><<
AZO AutoZone
$1,588.97 /

-6.68 (-0.42%)

AZO AutoZone
$1,588.97 /

-6.68 (-0.42%)

09/13/21 DA Davidson
AutoZone downgraded to Neutral from Buy at DA Davidson
08/27/21
Fly Intel: Top five analyst downgrades
08/27/21 Morgan Stanley
AutoZone downgraded to Equal Weight from Overweight at Morgan Stanley
08/27/21 Morgan Stanley
AutoZone downgraded to Equal Weight from Overweight at Morgan Stanley
AZO AutoZone
$1,588.97 /

-6.68 (-0.42%)

AZO AutoZone
$1,588.97 /

-6.68 (-0.42%)

Conference/Events
Morgan Stanley Asian gaming analyst to hold analyst/industry conference call » 20:15
09/20/21
09/20
20:15
09/20/21
20:15

Asiam Gaming &…

Asiam Gaming & Lodging Analyst Choudhary, along with Former Senior Legal Adviser to Macau, Antonie Lobo Vilela, discuss navigating the gaming law revision and concession renewal process on an Analyst/Industry conference call to be held on September 20 at 8:30 pm.

Hot Stocks
Hutchmed initiates Surtori-01 phase 3 trial of Sulanda in NEC » 20:02
09/20/21
09/20
20:02
09/20/21
20:02
HCM

Hutchmed

$38.24 /

-0.64 (-1.65%)

Hutchmed Limited…

Hutchmed Limited announces that it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and safety of surufatinib in combination with toripalimab compared with FOLFIRI to treat patients with advanced neuroendocrine carcinoma, or NEC, who have progression of disease or intolerable toxicity after previous first-line chemotherapy. The first patient was dosed on September 18, 2021 in China. Toripalimab is marketed as TUOYI in China by Shanghai Junshi Biosciences Co., Ltd.

ShowHide Related Items >><<
HCM Hutchmed
$38.24 /

-0.64 (-1.65%)

HCM Hutchmed
$38.24 /

-0.64 (-1.65%)

08/03/21 Jefferies
Hutchmed initiated with a Buy at Jefferies
07/13/21 Cantor Fitzgerald
Hutchmed price target raised to $45 from $40 at Cantor Fitzgerald
10/02/20 Deutsche Bank
Hutchison China MediTech initiated with a Buy at Deutsche Bank
HCM Hutchmed
$38.24 /

-0.64 (-1.65%)

HCM Hutchmed
$38.24 /

-0.64 (-1.65%)

Hot Stocks
HCA Healthcare to buy five Utah hospitals from Steward Health Care » 19:46
09/20/21
09/20
19:46
09/20/21
19:46
HCA

HCA Healthcare

$254.98 /

-3.78 (-1.46%)

HCA Healthcare and…

HCA Healthcare and Steward Health Care announced the signing of a definitive agreement for HCA Healthcare to acquire the operations of Steward Health Care's five Utah hospitals. HCA Healthcare also entered into an agreement to lease the related real estate from its owner following the expected closing. The hospitals will become part of HCA Healthcare's Mountain Division, which includes 11 hospitals in Utah, Idaho and Alaska.

ShowHide Related Items >><<
HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

09/09/21 Cowen
HCA's EBITDA outperformance remains underestimated, says Cowen
09/09/21 Cowen
HCA Healthcare initiated with an Outperform at Cowen
08/12/21 Barclays
HCA Healthcare assumed at Equal Weight from Overweight at Barclays
07/22/21 Barclays
HCA Healthcare price target raised to $275 from $225 at Barclays
HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

HCA HCA Healthcare
$254.98 /

-3.78 (-1.46%)

Hot Stocks
Equity Bancshares initiates 8c per share quarterly dividend » 19:18
09/20/21
09/20
19:18
09/20/21
19:18
EQBK

Equity Bancshares

$30.43 /

+0.11 (+0.36%)

The dividend is payable…

The dividend is payable on October 14, 2021 to stockholders of record at the close of business on September 30, 2021.

ShowHide Related Items >><<
EQBK Equity Bancshares
$30.43 /

+0.11 (+0.36%)

EQBK Equity Bancshares
$30.43 /

+0.11 (+0.36%)

Initiation
CapitaLand initiated with a Buy at Goldman Sachs » 19:16
09/20/21
09/20
19:16
09/20/21
19:16
CLLDY

CapitaLand

$5.73 /

-0.06 (-1.04%)

Goldman Sachs analyst…

Goldman Sachs analyst Xuan Tan initiated coverage of CapitaLand with a Buy rating and S$3.64 price target. The company has sharpened its focus as a real estate investment manager with the privatization of its development segment, the analyst tells investors in a research note. Xuan Tan sees benefits of the restructuring coming in the form of improved earnings visibility and margins.

ShowHide Related Items >><<
CLLDY CapitaLand
$5.73 /

-0.06 (-1.04%)

03/23/21 Goldman Sachs
CapitaLand initiated with a Buy at Goldman Sachs
Initiation
Rathbone Brothers initiated with an Overweight at Barclays » 19:12
09/20/21
09/20
19:12
09/20/21
19:12
RTBBF

Rathbone Brothers

$20.35 /

+ (+0.00%)

Barclays analyst Alex…

Barclays analyst Alex Medhurst initiated coverage of Rathbone Brothers with an Overweight rating and 2,500 GBp price target. The analyst believes that the stock trading below its average multiple is at odds with an improving growth outlook; the Saunderson House transaction addressing past concerns over a lack of scale and growth in financial planning; and a material gearing to positive trends in ESG investing.

ShowHide Related Items >><<
RTBBF Rathbone Brothers
$20.35 /

+ (+0.00%)

11/18/20 Berenberg
Rathbone Brothers upgraded to Buy from Hold at Berenberg
Downgrade
Quilter downgraded to Underweight from Equal Weight at Barclays » 19:10
09/20/21
09/20
19:10
09/20/21
19:10
QUILF

Quilter

$2.05 /

+ (+0.00%)

Barclays analyst Alex…

Barclays analyst Alex Medhurst downgraded Quilter to Underweight from Equal Weight with a price target of 130 GBp, down from 155 GBp. The analyst believes consensus is too optimistic that negative trends in the company's revenue margins and operating margins will slow or reverse. Medhurst added that revenue estimates may face further pressure due to recent RFP headcount reductions and that broad-based underperformance across business lines will take time to reverse.

ShowHide Related Items >><<
QUILF Quilter
$2.05 /

+ (+0.00%)

08/31/21 RBC Capital
Quilter price target lowered to 175 GBp from 185 GBp at RBC Capital
04/15/21 Credit Suisse
Quilter initiated with an Outperform at Credit Suisse
01/27/21 Barclays
Quilter price target raised to 145 GBp from 140 GBp at Barclays
11/19/20 Barclays
Quilter initiated with an Equal Weight at Barclays
Initiation
Brewin Dolphin initiated with an Overweight at Barclays » 19:07
09/20/21
09/20
19:07
09/20/21
19:07
BDNHF

Brewin Dolphin

$2.99 /

+ (+0.00%)

Barclays analyst Alex…

Barclays analyst Alex Medhurst initiated coverage of Brewin Dolphin with an Overweight rating and 430 GBp price target. The analyst said the Overweight rating was due to strong organic AUMA growth than comparable DFM businesses; improved distribution; and the potential for EPS upgrades. Medhurst believes a premium is merited.

Hot Stocks
Amgen wins patent case on Otezla » 19:03
09/20/21
09/20
19:03
09/20/21
19:03
AMGN

Amgen

$215.17 /

-4.42 (-2.01%)

Amgen "announced…

Amgen "announced that the U.S. District Court for the District of New Jersey has upheld patents that protect Amgen's psoriasis therapy Otezla in a patent infringement lawsuit against Sandoz and Zydus Pharmaceuticals, Inc. The asserted patents claim apremilast as a composition of matter, methods of treating psoriasis with apremilast, and crystalline forms of apremilast. The court found infringement and upheld the validity of four patents - three against each defendant -- but ruled against Amgen on claims in U.S. Patent No. 10,092,541 covering methods of treating psoriasis with apremilast according to a specific dosing schedule. Today's decision will prevent Sandoz and Zydus from making, using, selling, offering to sell, or importing each of their generic versions of Otezla until expiration of the COM patent, U.S. Patent No. 7,427,638, in Feb. 2028. The decision comes after the New Jersey court held a bench trial in June 2021. Prior to trial, Sandoz acknowledged that its generic version of Otezla infringes eight claims in U.S. Patent Nos. 7,427,638, 7,893,101, 8,455,536, and 10,092,541, and Zydus acknowledged that its generic version of Otezla infringes eight claims in U.S. Patent Nos. 7,427,638, 8,093,283, 8,455,536, and 10,092,541, leaving only the issues of whether Zydus's generic version of Otezla infringes U.S. Patent No. 7,893,101 and the validity of the asserted patent claims to be addressed by the court."

ShowHide Related Items >><<
AMGN Amgen
$215.17 /

-4.42 (-2.01%)

AMGN Amgen
$215.17 /

-4.42 (-2.01%)

09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Amgen to Equal Weight, sees better risk/reward elsewhere
09/07/21 Morgan Stanley
Amgen downgraded to Equal Weight from Overweight at Morgan Stanley
08/12/21 Goldman Sachs
Revolution Medicines downgraded to Neutral from Buy at Goldman Sachs
AMGN Amgen
$215.17 /

-4.42 (-2.01%)

AMGN Amgen
$215.17 /

-4.42 (-2.01%)

AMGN Amgen
$215.17 /

-4.42 (-2.01%)

On The Fly
Fly Intel: After-Hours Movers » 18:39
09/20/21
09/20
18:39
09/20/21
18:39
APRE

Aprea Therapeutics

$4.84 /

-0.275 (-5.38%)

, VRDN

Viridian Therapeutics

$10.52 /

-1.11 (-9.54%)

, GMAB

Genmab

$42.88 /

-0.16 (-0.37%)

, SGEN

Seagen

$159.09 /

+2.8 (+1.79%)

, SDC

SmileDirectClub

$6.48 /

-0.22 (-3.28%)

, HRI

Herc Holdings

$125.41 /

-4.1 (-3.17%)

, HLF

Herbalife Nutrition

$44.12 /

-0.285 (-0.64%)

, LEN

Lennar

$98.16 /

-3.17 (-3.13%)

, VRCA

Verrica Pharmaceuticals

$12.01 /

-0.045 (-0.37%)

, ROLL

RBC Bearings

$215.67 /

+2.62 (+1.23%)

, CFMS

Conformis

$1.70 /

-0.135 (-7.38%)

, KAR

KAR Auction

$15.73 /

-0.38 (-2.36%)

, PGR

Progressive

$92.21 /

-0.42 (-0.45%)

Check out this evening's…

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

SGEN Seagen
$159.09 /

+2.8 (+1.79%)

SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

ROLL RBC Bearings
$215.67 /

+2.62 (+1.23%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

GMAB Genmab
$42.88 /

-0.16 (-0.37%)

CFMS Conformis
$1.70 /

-0.135 (-7.38%)

APRE Aprea Therapeutics
$4.84 /

-0.275 (-5.38%)

APRE Aprea Therapeutics
$4.84 /

-0.275 (-5.38%)

08/20/21 JPMorgan
JPMorgan downgrades Aprea to Underweight on 'multiple overhangs'
08/20/21 JPMorgan
Aprea Therapeutics downgraded to Underweight from Neutral at JPMorgan
08/16/21 Berenberg
Aprea Therapeutics downgraded to Hold from Buy at Berenberg
08/16/21 H.C. Wainwright
Aprea Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
GMAB Genmab
$42.88 /

-0.16 (-0.37%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
SGEN Seagen
$159.09 /

+2.8 (+1.79%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

09/20/21 Stifel
Stifel cuts SmileDirectClub to Hold on market share loss, growth uncertainty
09/20/21 Stifel
SmileDirectClub downgraded to Hold from Buy at Stifel
08/13/21
Fly Intel: Top five analyst downgrades
08/13/21 Wolfe Research
SmileDirectClub downgraded to Peer Perform from Outperform at Wolfe Research
HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

09/16/21 Baird
Ashtead results positive for United Rentals and Herc, says Baird
07/23/21 Barclays
Herc Holdings price target raised to $135 from $128 at Barclays
07/22/21 Baird
Herc Holdings price target raised to $145 from $135 at Baird
07/14/21 Barclays
Herc Holdings price target raised to $128 from $115 at Barclays
HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

09/16/21 Citi
Herbalife selloff on guidance cut 'distinct overreaction,' says Citi
09/15/21 B. Riley
Herbalife Nutrition price target lowered to $61 from $70 at B. Riley
09/15/21 Jefferies
Herbalife's 20% pullback 'extreme' relative to guide down, says Jefferies
09/14/21 Jefferies
Herbalife Nutrition guidance cut 'a surprise,' says Jefferies
LEN Lennar
$98.16 /

-3.17 (-3.13%)

06/21/21 Argus
Lennar has an edge on many rivals, says Argus
06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Evercore ISI
Lennar price target raised to $160 from $121 at Evercore ISI
06/18/21 JPMorgan
JPMorgan upgrades Lennar with transformation not reflected in shares
VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

06/17/21 Needham
Verrica Pharmaceuticals's Ycanth offers superior efficacy to Novan, says Needham
06/01/21 Northland
Verrica Pharmaceuticals price target lowered to $19 from $24 at Northland
05/13/21 RBC Capital
Verrica Pharmaceuticals initiated with an Outperform at RBC Capital
03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
ROLL RBC Bearings
$215.67 /

+2.62 (+1.23%)

07/27/21 Truist
RBC Bearings price target raised to $225 from $175 at Truist
02/02/21 Truist
RBC Bearings price target raised to $140 from $118 at Truist
01/11/21 Truist
RBC Bearings upgraded to Hold from Sell at Truist
CFMS Conformis
$1.70 /

-0.135 (-7.38%)

03/04/21 Canaccord
Conformis undervalued despite momentum, says Canaccord
KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

08/04/21 JPMorgan
ACV Auctions upgraded to Overweight from Neutral at JPMorgan
05/24/21 JPMorgan
KAR Auction price target raised to $24 from $21 at JPMorgan
05/21/21 BofA
KAR Auction upgraded to Buy from Underperform at BofA
02/18/21
Fly Intel: Top five analyst downgrades
PGR Progressive
$92.21 /

-0.42 (-0.45%)

08/17/21 Evercore ISI
Progressive added to 'Tactical Underperform List' at Evercore ISI
08/16/21 Wolfe Research
Progressive initiated with an Underperform at Wolfe Research
07/16/21 Barclays
Progressive price target lowered to $84 from $86 at Barclays
07/09/21 BofA
Progressive added to US 1 List; Arch Capital removed at BofA
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

SGEN Seagen
$159.09 /

+2.8 (+1.79%)

SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

ROLL RBC Bearings
$215.67 /

+2.62 (+1.23%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

CFMS Conformis
$1.70 /

-0.135 (-7.38%)

APRE Aprea Therapeutics
$4.84 /

-0.275 (-5.38%)

  • 22
    Sep
  • 21
    Sep
  • 23
    Mar
  • 12
    Feb
  • 24
    Nov
  • 19
    Nov
  • 24
    Sep
SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

ROLL RBC Bearings
$215.67 /

+2.62 (+1.23%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

GMAB Genmab
$42.88 /

-0.16 (-0.37%)

CFMS Conformis
$1.70 /

-0.135 (-7.38%)

VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

APRE Aprea Therapeutics
$4.84 /

-0.275 (-5.38%)

Hot Stocks
KAR Auction withdraws FY21 guidance due to chip shortage related disruption » 18:36
09/20/21
09/20
18:36
09/20/21
18:36
KAR

KAR Auction

$15.73 /

-0.38 (-2.36%)

KAR Auction Services…

KAR Auction Services "announced that as a result of the continued disruption caused by the chip shortage and the corresponding lack of visibility into used vehicle volumes in its marketplaces, the company is withdrawing its previously provided financial outlook for FY21. The company sees Q3 adjusted EBITDA of $95M-$100M and expects approximately 2.6M vehicles sold in 2021. Due to the market uncertainty, the company does not intend to provide fourth quarter expectations at this time."

ShowHide Related Items >><<
KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

08/04/21 JPMorgan
ACV Auctions upgraded to Overweight from Neutral at JPMorgan
05/24/21 JPMorgan
KAR Auction price target raised to $24 from $21 at JPMorgan
05/21/21 BofA
KAR Auction upgraded to Buy from Underperform at BofA
02/18/21
Fly Intel: Top five analyst downgrades
KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

Hot Stocks
Airbnb CEO: Our model is very adaptable » 18:24
09/20/21
09/20
18:24
09/20/21
18:24
ABNB

Airbnb

$161.65 /

-5.325 (-3.19%)

In an interview on…

In an interview on CNBC's Mad Money, Brian Chesky said 55% of Airbnb's hosts are women. The company's model is incredibly adaptable and it's always innovating, he noted. It's currently in over 100,000 communities. Airbnb used to be an alternative way to travel, but now it's becoming the default option, he added.

ShowHide Related Items >><<
ABNB Airbnb
$161.65 /

-5.325 (-3.19%)

ABNB Airbnb
$161.65 /

-5.325 (-3.19%)

09/15/21 Tigress Financial
Airbnb shares going to $206 in 12 months, says Tigress Financial
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 Goldman Sachs
Airbnb initiated with a Sell at Goldman Sachs
ABNB Airbnb
$161.65 /

-5.325 (-3.19%)

  • 10
    Dec
ABNB Airbnb
$161.65 /

-5.325 (-3.19%)

ABNB Airbnb
$161.65 /

-5.325 (-3.19%)

ABNB Airbnb
$161.65 /

-5.325 (-3.19%)

Earnings
Havertys says Q3-to-date sales up 21.2% vs. last year » 18:19
09/20/21
09/20
18:19
09/20/21
18:19
HVT

Havertys

$34.58 /

+0.69 (+2.04%)

The company states:…

The company states: "Havertys sales for the third quarter to date of 2021 are up approximately 21.2% over the same period last year and comparable store sales are up 19.5%. Written business for the third quarter to date over the same period last year is up 2.7% and comparable written business is up 1.0%. This pace of business compares to the full third quarter of 2020 over 2019 and that period's increases in sales of 3.9% and written business of 22.8%." CEO Clarence Smith says: "Our business continues to be strong as we work to deliver customers' purchases and help them create their vision of home. Merchandise availability impacts our business and supply chain disruptions remain a concern, particularly as lockdowns continue in Vietnam."

ShowHide Related Items >><<
HVT Havertys
$34.58 /

+0.69 (+2.04%)

HVT Havertys
$34.58 /

+0.69 (+2.04%)

11/24/20 UBS
RH price target raised to $450 from $380 at UBS
10/07/20 Sidoti
Havertys upgraded to Buy from Neutral at Sidoti
HVT Havertys
$34.58 /

+0.69 (+2.04%)

HVT Havertys
$34.58 /

+0.69 (+2.04%)

Hot Stocks
Vintage Wine Estates says Russell Joy to succeed Jeff Nicholson as COO » 18:11
09/20/21
09/20
18:11
09/20/21
18:11
VWE

Vintage Wine Estates

$10.48 /

-0.08 (-0.76%)

Vintage Wine Estates…

Vintage Wine Estates announced the succession plan for its COO. Russell Joy, who brings over 20 years of wine industry experience spanning finance and operations, will be appointed COO effective November 1, succeeding Jeff Nicholson, who will retire from the company effective October 29. Joy has held key roles in the wine industry most recently as General Manager of Napa Wine Company where he managed the upgrading of its facility while leading a culture change.

ShowHide Related Items >><<
VWE Vintage Wine Estates
$10.48 /

-0.08 (-0.76%)

VWE Vintage Wine Estates
$10.48 /

-0.08 (-0.76%)

07/07/21 Cowen
Vintage Wine Estates initiated with an Outperform at Cowen
07/07/21 Cowen
Vintage Wine Estates initiated with an Outperform at Cowen
07/02/21
Fly Intel: Top five analyst initiations
07/02/21 Citi
Vintage Wine Estates initiated with a Buy at Citi
VWE Vintage Wine Estates
$10.48 /

-0.08 (-0.76%)

Upgrade
Vail Resorts upgraded to Overweight from Sector Weight at KeyBanc » 18:09
09/20/21
09/20
18:09
09/20/21
18:09
MTN

Vail Resorts

$309.85 /

+1.35 (+0.44%)

KeyBanc analyst Brett…

KeyBanc analyst Brett Andress upgraded Vail Resorts to Overweight from Sector Weight with a $355 price target. The analyst said his previous view that Vail would suffer from demand hurdles in fiscal 2021 was wrong, and that looking into fiscal 2022, destination demand indicators for this upcoming season are above pre-pandemic levels, even with Delta in the background. Andress also noted that metrics he uses to track intra-quarter pass sales appear robust, painting a path for unit sales to compare healthy versus fiscal 2020 levels.

ShowHide Related Items >><<
MTN Vail Resorts
$309.85 /

+1.35 (+0.44%)

MTN Vail Resorts
$309.85 /

+1.35 (+0.44%)

06/08/21 BofA
Vail Resorts price target raised to $375 from $365 at BofA
06/08/21 Deutsche Bank
Vail Resorts price target raised to $298 from $294 at Deutsche Bank
06/01/21 Deutsche Bank
Vail Resorts named 'Catalyst Call: Buy Idea' at Deutsche Bank
04/26/21 Truist
Vail Resorts price target raised to $308 from $292 at Truist
MTN Vail Resorts
$309.85 /

+1.35 (+0.44%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.